Eli Lilly & Co. Inc.'s stock (LLY) rose 2.3% Wednesday, after the company said its Zepbound weight-loss drug was more effective than rival Novo Nordisk's Wegovy in a head-to-head study.
Shares of Eli Lilly climbed early Wednesday after the drugmaker detailed a study showing that its blockbuster weight-loss drug Zepbound helped patients shed more pounds than Wegovy from rival Novo ...
Eli Lilly said patients taking its obesity drug Zepbound lost 47% more weight than those who were given Novo Nordisk's Wegovy ...
The bears might point out that Eli Lilly's shares still look too expensive: The company's trailing price-to-earnings (P/E) ...
People who took Zepbound, Eli Lilly’s weight loss drug, shed more pounds than those on Novo Nordisk’s Wegovy in a clinical ...
Amgen’s AMGN stock has declined 12.1% in the past month. Late last month, Amgen announced the much-awaited 52-week top-line ...
Unlike its rivals, which require weekly injections, MariTide offers the potential for monthly or less frequent dosing ...
Ozempic and Wegovy might be making it harder for physicians to guide patients toward lifestyle changes − the real key to long ...
LSU football was handed a gut-wrenching loss in Week 11 by No. 11 Alabama, a loss that significantly impacted its College Football Playoff odds and path. Already dealing with a small room for ...
Flashes of Navy and Gold ran all over Florida State football as Notre Dame handed the Seminoles a 52-3 loss Saturday night. In front of a nearly sold-out Notre Dame Stadium, the Fighting Irish (8 ...